Nevro, Globus

Jefferies analyst Matthew Taylor revised the stock rating for Nevro Corp (NYSE:NVRO), elevating it from Underperform to Hold. Accompanying this upgrade, the price target also saw an increase to $5.85, ...
In a report released on February 7, Nathan Treybeck from Wells Fargo maintained a Hold rating on Nevro Corp (NVRO – Research Report), with a ...
Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...
Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Piper Sandler analyst Adam Maeder upgraded shares of Nevro Corp (NYSE:NVRO), a medical device company with a market ...
Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition ...
Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...